CDC. COVID Data Tracker. In: Prevention CfDCa, editor.: US Department of Health & Human Services; 2023.

PAHO. Coronavirus disease (COVID-19). In: Organization PAH, editor.: World Health Organization; 2023.

Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021;385(24):2241–51.

Article  CAS  PubMed  Google Scholar 

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–16.

Article  CAS  PubMed  Google Scholar 

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.

Article  CAS  PubMed  Google Scholar 

Bruxvoort KJ, Sy LS, Qian L, Ackerson BK, Luo Y, Lee GS, et al. Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: interim results from a prospective observational cohort study. Lancet Reg Health Am. 2022;6: 100134.

PubMed  Google Scholar 

Kow CS, Hasan SS. Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies. Inflammopharmacology. 2021;29(4):1075–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tenforde MW, Patel MM, Gaglani M, Ginde AA, Douin DJ, Talbot HK, et al. Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults—United States, August–December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(4):118–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moreira ED Jr, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, et al. Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine. N Engl J Med. 2022;386(20):1910–21.

Article  CAS  PubMed  Google Scholar 

Teo SP. Review of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273. J Pharm Pract. 2022;35(6):947–51.

Article  PubMed  Google Scholar 

Lee A, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376: e068632.

Article  PubMed  Google Scholar 

Chemaitelly H, Ayoub HH, Tang P, Coyle P, Yassine HM, Al Thani AA, et al. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. Lancet Infect Dis. 2023;23(7):816–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021;385(24): e83.

Article  CAS  PubMed  Google Scholar 

Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duly K, Farraye FA, Bhat S. COVID-19 vaccine use in immunocompromised patients: a commentary on evidence and recommendations. Am J Health Syst Pharm. 2022;79(2):63–71.

Article  PubMed  Google Scholar 

FDA. Factsheet for healthcare providers administering vaccine (vaccination providers) emergency use authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). U.S. Food and Drug Administration; 2022.

FDA. Vaccine Information Fact Sheet for Recipients and Caregivers About Comirnaty (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19). US Food and Drug Administration; 2022.

Mues KE, Kirk B, Patel DA, Gelman A, Chavers LS, Talarico CA, et al. Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States. Vaccine. 2022;40(47):6730–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ku JH, Sy LS, Qian L, Ackerson BK, Luo Y, Tubert JE, et al. Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: a prospective observational cohort study. Vaccine. 2023;41(24):3636–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078–90.

Article  CAS  PubMed  Google Scholar 

Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093–100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Haeussler K, Spellman A, Phillips LE, Ramiller A, Bausch-Jurken MT, et al. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework. Front Immunol. 2023;14:1204831.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stumpf J, Siepmann T, Lindner T, Karger C, Schwöbel J, Anders L, et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur. 2021;9: 100178.

Article  PubMed  PubMed Central  Google Scholar 

Fernandes Q, Inchakalody VP, Merhi M, Mestiri S, Taib N, Moustafa Abo El-Ella D, et al. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med. 2022;54(1):524–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

CDC. Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States. In: Prevention CfDCa, editor.: US Department of Health & Human Services; 2023.

Kluberg SA, Hou L, Dutcher SK, Billings M, Kit B, Toh S, et al. Validation of diagnosis codes to identify hospitalized COVID-19 patients in health care claims data. Pharmacoepidemiol Drug Saf. 2022;31(4):476–80.

Article  CAS  PubMed  Google Scholar 

Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.

Article  PubMed  Google Scholar 

Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring frailty in Medicare data: development and validation of a claims-based frailty index. J Gerontol A Biol Sci Med Sci. 2018;73(7):980–7.

Article  PubMed  Google Scholar 

Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–79.

Article  PubMed  PubMed Central  Google Scholar 

Schulte PJ, Mascha EJ. Propensity score methods: theory and practice for anesthesia research. Anesth Analg. 2018;127(4):1074–84.

Article  PubMed  Google Scholar 

Wang L, Davis PB, Kaelber DC, Volkow ND, Xu R. Comparison of mRNA-1273 and BNT162b2 vaccines on breakthrough SARS-CoV-2 infections, hospitalizations, and death during the delta-predominant period. JAMA. 2022;327(7):678–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Florea A, Sy LS, Qian L, Ackerson BK, Luo Y, Tubert JE, et al. Effectiveness of messenger RNA-1273 vaccine booster against coronavirus disease 2019 in immunocompetent adults. Clin Infect Dis. 2023;76(2):252–62.

Article  CAS  PubMed